CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CLBH589DUS108T
- 23 Mar 2018 Status changed from not yet recruiting to recruiting.
- 08 Feb 2018 Planned End Date changed from 16 Sep 2023 to 16 May 2024.
- 08 Feb 2018 Planned primary completion date changed from 16 Sep 2020 to 16 May 2021.